Yonsei Med J.  2000 Oct;41(5):563-569. 10.3349/ymj.2000.41.5.563.

In vitro activities of quinupristin/dalfopristin and eight other antimicrobial agents against 360 clinical isolates from Korea

Affiliations
  • 1Department of Clinical Pathology, University of Ulsan College of Medicine and Asan Medical Center, Seoul, Korea. mnkim@www.amc.seoul.kr
  • 2Clinical Research Institute, College of Medicine, The Catholic University, Seoul, Korea.
  • 3Department of Internal Medicine, College of Medicine, The Catholic University, Seoul, Korea.

Abstract

The emergence of multi-drug resistant gram-positive cocci such as methicillin-resistant (MR) staphylococci, vancomycin-resistant (VR) enterococci, and vancomycin-intermediate resistant S. aureus (VISA) has given new urgency to the development of new antimicrobial agents. One of these is quinupristin/dalfopristin (Q/D). We decided to determine the susceptibility of gram-positive cocci isolated at two university hospitals in Seoul to Q/D and compare the results with eight other antimicrobial agents. We investigated 120 isolates of S. aureus including 49 MRSAs and one VISA, 120 isolates of coagulase negative staphylococci (CNS), 64 E. faecalis and 56 E. faecium, including seven strains of VR E. faecium. Minimum inhibitory concentrations (MICs) and minimal bactericidal concentrations (MBCs) for several antimicrobials, including vancomycin and Q/D, were determined by broth microdilution. All S. aureus including VISA were susceptible to Q/D. Q/D MIC90 for both methicillin-susceptible S. aureus (MSSA) and MRSA was 0.25 g/mL. 49 (87.5%) of 56 E. faecium including six of seven VR E. faecium were susceptible to Q/D. E. faecalis were not susceptible to Q/D (only 1.5% susceptible), but were inhibited by ampicillin (94% susceptible) or vancomycin (95%). CNS was susceptible to Q/D (96% susceptible) and vancomycin (100% susceptible). One of 38 staphylococci and two of 17 E. faecium were tolerant to Q/D. In conclusion, Q/D showed excellent activity against all species of gram-positive cocci including MRSA, VISA, and VR E. faecium except E. faecalis, and may provide a valuable option for the treatment of infections caused by these emerging nosocomial pathogens of gram-positive cocci.

Keyword

Quinupristin/dalfopristin (Q/D); multi-drug resistant; MRSA; enterococci

MeSH Terms

Antibiotics/pharmacology*
Antibiotics, Peptide/pharmacology*
Coagulase/analysis
Enterococcus faecalis/drug effects
Enterococcus faecium/drug effects
Human
Korea
Microbial Sensitivity Tests*
Staphylococcus/enzymology
Staphylococcus/drug effects
Staphylococcus aureus/drug effects
Support, Non-U.S. Gov'tn
Virginiamycin/pharmacology*
Virginiamycin/analogs & derivatives*
Full Text Links
  • YMJ
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr